Observational analyses can complement randomized clinical trial findings for the study of HPV vaccine effectiveness

Led by researchers at NDORMS as part of the Data Analysis and Real World Interrogation Network (DARWIN EU) initiative, a new ...
CIDRAP

Vitamin D supplements don’t cut COVID health care use, symptom severity, trial shows

Per-protocol analyses, however, suggested a nonsignificant trend toward a lower prevalence of long COVID at two months (OR, 0 ...
UroToday

EAU 2026: CAPTAIN: Randomized Controlled Trial Evaluating MRI-Guided TULSA Versus Robotic Prostatectomy – Initial Perioperative Outcomes

The 2026 European Association of Urology (EAU) annual meeting featured a late-breaking abstracts session and a presentation ...
GlobalData on MSN

Mirum concludes Phase III EXPAND trial enrolment for Livmarli

The double-blind, randomised, placebo-controlled trial will assess the efficacy and safety of Livmarli in both children and ...
The New England Journal of Medicine

Prehospital Whole Blood in Traumatic Hemorrhage — a Randomized Controlled Trial

Whole-blood transfusion has recently gained favor in the management of severe hemorrhage; however, data from large clinical trials evaluating its clinical effectiveness and safety are lacking. We ...
MedPage Today

Cannabinoids for Mental, Substance Use Disorders 'Rarely Justified,' Study Suggests

Cannabinoids may reduce symptoms of some substance use and mental disorders, but the quality of evidence was mostly low in a systematic review and meta-analysis. The only finding of benefit with a ...
ascopubs.org

Effect of an Invitation or the Effect of Participation: What Should Randomized Controlled Trials of Cancer Screening Examine?

Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial Earlier detection of cancer offers an opportunity to ...

International mpox trial finds no clinical benefit from tecovirimat

An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox ...